Search Within

Andrew Jeffrey Dunbar

  1. "Center for Molecular Imaging and Biotechnology"
Formats
  1. Journal Article (10)
  2. Meeting Abstract (9)
  3. Editorial (1)
  4. Research Letter (1)
  5. Review (1)
Groups
  1. Adult Leukemia (22)
  2. Center for Hematologic Malignancies (22)
  3. Center for Molecular Imaging and Biotechnology (22)
  4. Department of Medicine (22)
  5. Executive Committee, Center for Hematologic Malignancies (22)
  6. GSK Faculty (22)

More Groups

People
  1. Ross Levine (22)
  2. Young Park (9)
  3. Anthony Martinez Benitez (4)
  4. Mirko Farina (4)
  5. Richard Koche (4)
  6. Sheng Cai (4)

More People

Years
  1. 2024 (5)
  2. 2022 (4)
  3. 2021 (3)
  4. 2020 (5)
  5. 2019 (4)
  6. 2017 (1)
Publications
  1. Blood (9)
  2. Haematologica (3)
  3. Cell Reports (2)
  4. Cancer Cell (1)
  5. Cancer Discovery (1)
  6. Cells (1)

More Publications

Publishers
  1. American Society of Hematology (9)
  2. Cell Press (3)
  3. Ferrata Storti Foundation (3)
  4. American Association for Cancer Research (2)
  5. Elsevier Inc. (1)
  6. Frontiers Media S.A. (1)

More Publishers

Results (22)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancy
    Journal Article

    Bowman, R. L.; Dunbar, A. J.; Mishra, T.; Xiao, W.; Waarts, M. R.; Maestre, I. F.; Eisman, S. E.; Cai, L.; Mowla, S.; Shah, N.; more...
    Cancer Cell (2024)

    Fulltext@MSK | Save
  • Jak2(V617F) reversible activation shows its essential requirement in myeloproliferative neoplasms
    Journal Article

    Dunbar, A. J.; Bowman, R. L.; Park, Y. C.; O'Connor, K.; Izzo, F.; Myers, R. M.; Karzai, A.; Zaroogian, Z.; Kim, W. J.; Fernandez-Maestre, I.; more...
    Cancer Discovery (2024)

    Fulltext@MSK | Save
  • Development of resistance to type II JAK2 inhibitors in MPN depends on AXL kinase and is targetable
    Journal Article

    Codilupi, T.; Szybinski, J.; Arunasalam, S.; Jungius, S.; Dunbar, A. C.; Stivala, S.; Brkic, S.; Albrecht, C.; Vokalova, L.; Yang, J. L.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Suppression of IL-1β promotes beneficial accumulation of fibroblast-like cells in atherosclerotic plaques in clonal hematopoiesis
    Journal Article

    Fidler, T. P.; Dunbar, A.; Kim, E.; Hardaway, B.; Pauli, J.; Xue, C.; Abramowicz, S.; Xiao, T.; O'Connor, K.; Sachs, N.; more...
    Nature Cardiovascular Research (2024)

    Fulltext@MSK | Save
  • Non-canonical Hedgehog signaling mediates profibrotic hematopoiesis-stroma crosstalk in myeloproliferative neoplasms
    Journal Article

    Pritchard, J. E.; Pearce, J. E.; Snoeren, I. A. M.; Fuchs, S. N. R.; Götz, K.; Peisker, F.; Wagner, S.; Benabid, A.; Lutterbach, N.; Klöker, V.; more...
    Cell Reports (2024)

    Fulltext@MSK | Save
  • The second generation type II JAK2 inhibitor, AJ1-10502, demonstrates enhanced selectivity, improved therapeutic efficacy and reduced mutant cell fraction compared to type I JAK2 inhibitors in models of myeloproliferative neoplasms (MPNs)
    Meeting Abstract

    Rai, S.; Stetka, J.; Usart, M.; Hao-Shen, H.; Park, Y.; Houston, R.; Martinez Benitez, A. R.; Wereski, M.; Guzzardi, E.; Persaud, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A risk-adapted study to assess the efficacy of enasidenib and subsequent response-driven addition of azacitidine for newly diagnosed IDH2-mutant AML patients: 3-year follow-up
    Meeting Abstract

    Stein, E.; Cai, S. F.; Huang, Y.; Dunbar, A.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W. G.; Schiller, G. J.; Olin, R. L.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • JAK2(V617F) reversible activation shows an essential requirement for JAK2(V617F) in myeloproliferative neoplasms (MPNs)
    Meeting Abstract

    Dunbar, A.; Bowman, R. L.; Park, Y.; Izzo, F.; Myers, R. M.; Karzai, A.; Kim, W. J.; Maestre, I. F.; Waarts, M. R.; Nazir, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • The CXCR1/CXCR2 inhibitor reparixin alters the development of myelofibrosis in the Gata1(low) mice
    Journal Article

    Verachi, P.; Gobbo, F.; Martelli, F.; Martinelli, A.; Sarli, G.; Dunbar, A.; Levine, R. L.; Hoffman, R.; Massucci, M. T.; Brandolini, L.; more...
    Frontiers in Oncology (2022)

    Fulltext@MSK | Save
  • Comparative mutational profiling of hematopoietic progenitor cells and circulating endothelial cells (CECs) in patients with primary myelofibrosis
    Journal Article

    Farina, M.; Bernardi, S.; Polverelli, N.; D’Adda, M.; Malagola, M.; Bosio, K.; Re, F.; Almici, C.; Dunbar, A.; Levine, R. L.; more...
    Cells (2021)

    Fulltext@MSK | Save